Stockscreener 앱 받기
0.906
2.97%
0.0261
시장 영업 전:
.88
-0.026
-2.87%
전일 마감가:
$0.8799
열려 있는:
$0.85
하루 거래량:
2.78M
Relative Volume:
0.44
시가총액:
$29.62M
수익:
-
순이익/손실:
$-563.30K
주가수익비율:
-4.5391
EPS:
-0.1996
순현금흐름:
$-22.23M
1주 성능:
+92.72%
1개월 성능:
+86.80%
6개월 성능:
+1.36%
1년 성능:
-56.75%
1일 변동 폭
$0.8306
$0.9408
1주일 범위
$0.4384
$1.59
52주 변동 폭
$0.38
$2.05
Promis Neurosciences Inc Stock (PMN) Company Profile
명칭
Promis Neurosciences Inc
전화
416-847-6898
주소
SUITE 200, 1920 YONGE STREET, TORONTO
PMN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.906 | 28.76M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
Is ProMIS Neurosciences Inc. stock a growth or value playFree Predictions - jammulinksnews.com
What analysts say about ProMIS Neurosciences Inc. stockFree Investment Risk Control - Autocar Professional
When is the best time to buy ProMIS Neurosciences Inc. stockHigh-impact stock picks - jammulinksnews.com
Will ProMIS Neurosciences Inc. stock split in the near futureConsistent triple-digit returns - jammulinksnews.com
ProMIS Neurosciences Gains FDA Fast Track for PMN310 - The Globe and Mail
Is ProMIS Neurosciences Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede - Cantech Letter
Alzheimer’s stock triples after FDA Fast-Track Designation - MSN
ProMIS Neurosciences Plunges 24.56% Intraday—Is the FDA Fast Track Outpacing Investor Sentiment? - AInvest
ProMIS Neurosciences Plunges 28% Intraday—Is This the Catalyst No One Saw Coming? - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyBreakout Level Watch - Newser
Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential - TipRanks
ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire
What drives ProMIS Neurosciences Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com
ProMIS Neurosciences announces $0.8M registered direct offering - TipRanks
ProMIS Neurosciences announces private placement financing - TipRanks
ProMIS Neurosciences stock gets FDA Fast Track designation for PMN310 - Investing.com
ProMIS Neurosciences (PMN) Secures Funding to Enhance Therapeuti - GuruFocus
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times
ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus
ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310 - Nasdaq
ProMIS Neurosciences Drops 9.82% Amid ICICI Bank's Strong Earnings - AInvest
ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan
Alzheimer's Treatment Pioneer ProMIS Secures New Funding to Accelerate PMN310 Clinical Trials - Stock Titan
ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia
3 Penny Stocks to Watch Now, 7/22/25 - TipRanks
ProMIS Neurosciences Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - jammulinksnews.com
ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com
ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail
Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse
ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest
ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest
Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest
ProMIS Neurosciences: Stock Surge Insight - StocksToTrade
ProMIS Neurosciences Soars 157% on FDA Fast Track Designation – What’s Fueling This Volatile Rally? - AInvest
ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com
ProMIS Neurosciences Surges: Analyzing Recent Moves - timothysykes.com
ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks
ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Why ProMIS Is Rising In Pre-market? - Nasdaq
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug By Investing.com - Investing.com South Africa
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug - Investing.com Australia
ProMIS Neurosciences granted Fast Track designation by FDA for PMN310 - TipRanks
ProMIS Neurosciences Granted Fast Track Designation by U.S. - GlobeNewswire
FDA Fast-Tracks Revolutionary Alzheimer's Drug Promising Fewer Side Effects Than Current Treatments - Stock Titan
Promis Neurosciences Inc (PMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):